Advancing Drug Development Through Bayesian Approaches: Insights Drawn From Practical Experience in Pharmaceutical R&D
Pharmaceutical Statistics · 2026-11 · 25 (6)
DOI: 10.1002/pst.70147 ↗Kurz gefasst
Fachartikel in der Zeitschrift Pharmaceutical Statistics, online erschienen am 11.11.2026. Verfasst von Telba Irony und 3 weiteren Autor:innen. Beteiligte Einrichtung: Quantitative Sciences and Clinical Pharmacology, Johnson & Johnson, Innovative Medicine, Spring House, Pennsylvania, USA. Hauptthemen laut MEDLINE: Drug Development, Research Design, Clinical Trials as Topic. Die Arbeit nennt 48 Literaturangaben.
Abstract (Originalsprache)
Bayesian approaches are increasingly used in drug development to optimize clinical trial design and analysis by formally integrating prior knowledge, quantifying uncertainty, and supporting decision making throughout the development lifecycle. Nevertheless, broader implementation in confirmatory settings remains constrained by perceived technical complexity and uncertainty regarding regulatory acceptance. This article presents practical applications drawn from our experience, with a focus on how Bayesian thinking can improve drug development. We start with Bayesian methods for borrowing information in clinical trials and explore applications such as external control augmentation and treatment effect extrapolation. We discuss key challenges, including demonstration of exchangeability, over‐borrowing, bias, and potential type I error inflation, and outline mitigation strategies such as dynamic borrowing and sensitivity analyses. Regulatory implications of these approaches are illustrated through two pediatric case studies, one unsuccessful and one accepted, highlighting features that influence regulatory acceptability. We then present examples showing how Bayesian models can enhance analytical decision‐making during trial conduct even when the primary analyses rely on frequentist methods. Next, we introduce Assurance and Conditional Assurance and demonstrate how these Bayesian metrics can be used to optimize development strategies, including phase progression decisions, number of registrational trials, futility rules, enrichment strategies, and alpha spending. Finally, we illustrate how Bayesian models can support trial operations by forecasting and monitoring the probability of operational success. Overall, the article shows how Bayesian approaches, even when used alongside frequentist methods, can strengthen trial design and analysis, improve efficiency, and enhance transparency across drug development.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Quantitative Sciences and Clinical Pharmacology, Johnson & Johnson, Innovative Medicine, Spring House, Pennsylvania, USA.
ORCID-Profile: Telba Irony, Vladimir Dragalin
Zitieren
APA
Irony, T., Mielke, T., Ohrn, F., & Dragalin, V. (2026). Advancing Drug Development Through Bayesian Approaches: Insights Drawn From Practical Experience in Pharmaceutical R&D. Pharmaceutical Statistics, 25(6). https://doi.org/10.1002/pst.70147
Vancouver
Irony T, Mielke T, Ohrn F, Dragalin V. Advancing Drug Development Through Bayesian Approaches: Insights Drawn From Practical Experience in Pharmaceutical R&D. Pharmaceutical Statistics. 2026;25(6). doi:10.1002/pst.70147
BibTeX
@article{Irony2026,
author = {Irony, Telba and Mielke, Tobias and Ohrn, Fredrik and Dragalin, Vladimir},
title = {Advancing Drug Development Through Bayesian Approaches: Insights Drawn From Practical Experience in Pharmaceutical R&D},
journal = {Pharmaceutical Statistics},
year = {2026},
volume = {25},
number = {6},
doi = {10.1002/pst.70147}
}
EUVIMED